Cabozantinib: an Active Novel Multikinase Inhibitor in Renal Cell Carcinoma. - Wikidata - wikimedia - TriplyDB

Cabozantinib: an Active Novel Multikinase Inhibitor in Renal Cell Carcinoma.

Cabozantinib: an Active Novel Multikinase Inhibitor in Renal Cell Carcinoma.

http://www.wikidata.org/entity/Q37672483

about

A novel multikinase inhibitor R8 exhibits potent inhibition on cancer cells through both apoptosis and autophagic cell death.Novel concepts of antiangiogenic therapies in metastatic renal cell cancer.Overexpression of CKAP4 is Associated with Poor Prognosis in Clear Cell Renal Cell Carcinoma and Functions via Cyclin B Signaling.Tyrosine-Kinase Inhibitors for Treatment in Hemodialysis Patients on Kidney Transplant Waiting List. Comment on: Nakai et al.Cabozantinib is well tolerated in acute myeloid leukemia and effectively inhibits the resistance-conferring FLT3/tyrosine kinase domain/F691 mutation.Cabozantinib in Patients with Advanced Merkel Cell Carcinoma.Crosstalk between VEGFR and other receptor tyrosine kinases for TKI therapy of metastatic renal cell carcinoma.High IDO-1 expression in tumor endothelial cells is associated with response to immunotherapy in metastatic renal cell carcinoma.Renin-angiotensin inhibitors reprogram tumor immune microenvironment: A comprehensive view of the influences on anti-tumor immunity

P2860

Q44869860-1C2B4057-CDE4-4657-9B64-0BC8A2C1C068 Q47144667-21110B2D-A358-4EFD-9116-C01A7A628222 Q47151111-FD5B3EB1-33A2-4C00-B935-12EB98DE22FB Q48112913-171842DE-A56F-461E-8E5E-561D14DAE370 Q48273276-D00B9632-278B-4C74-A658-5B912E039F4E Q51751201-BDFB23C2-988B-45E6-8B66-B3FDC86C2170 Q52661758-E5536CAF-197B-4247-A697-3D3084B705B5 Q52677218-207E3531-4A6A-4EF8-8DB8-C08E47BA435D Q59125636-023E1134-0D82-4CC7-9E51-1E9403079BBD

P2860

Cabozantinib: an Active Novel Multikinase Inhibitor in Renal Cell Carcinoma.

http://www.wikidata.org/entity/Q37672483

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on February 2017

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Cabozantinib: an Active Novel Multikinase Inhibitor in Renal Cell Carcinoma.

@en

Cabozantinib: an Active Novel Multikinase Inhibitor in Renal Cell Carcinoma.

@nl

type

label

Cabozantinib: an Active Novel Multikinase Inhibitor in Renal Cell Carcinoma.

@en

Cabozantinib: an Active Novel Multikinase Inhibitor in Renal Cell Carcinoma.

@nl

prefLabel

Cabozantinib: an Active Novel Multikinase Inhibitor in Renal Cell Carcinoma.

@en

Cabozantinib: an Active Novel Multikinase Inhibitor in Renal Cell Carcinoma.

@nl

P1433

Q37672483-84923739-A207-4718-9ECB-562F5165BAE7

P1476

Q37672483-EA83963E-5798-4BD7-927B-0C8B783755A0

P2093

Q37672483-48A3A3B9-43EB-43AB-8CB3-970B1EB1AB75

Q37672483-B3E12625-9555-45A2-B709-2209E31DBB48

Q37672483-E3A891E2-2854-4E7A-997F-51915C21827C

P275

Q37672483-AF592602-E5D5-43A2-BEEF-3148406E7899

P2860

Q37672483-02966C36-3282-4FD3-B7E2-533542E88A57

Q37672483-07A54653-9940-417C-A246-301CAD8D9983

Q37672483-1AA075E8-F953-4FB1-9D9A-F26B33CB0BA5

Q37672483-2A0C351E-D3BB-4C9B-9F2E-CF8A35424841

Q37672483-38463E8B-D047-4588-8AA2-B3711ADC6ED0

Q37672483-3BB307E0-81BC-410E-B6EE-F320C213979D

Q37672483-40EB33AE-8F0B-4925-81E2-0725E59F984C

Q37672483-4215C571-2A76-47C2-97EC-75C2442565F0

Q37672483-455EC812-F731-4713-9E76-B66811D5AC68

Q37672483-4A74AA27-98B6-4168-A919-532962905752

P2888

Q37672483-5DFCB6A4-4F0E-41BE-A39C-A29BFED18AFC

P304

Q37672483-5DA5AFB0-08E1-40F6-9FCE-001435B89E2F

P31

Q37672483-85D849EB-DFF2-41CC-A92D-AA9C44A08969

Q37672483-8DA87927-74EB-4BF4-8988-3AEF625435B4

P356

Q37672483-4355B762-2258-4101-B4CF-FBBCC2C22932

P433

Q37672483-6AD04043-2CE3-465E-B986-68CACCA207A0

P478

Q37672483-F9239260-BC4B-4601-AEAE-265BAD301C92

P5008

Q37672483-C7A1F5E8-9D46-46E1-A939-6DD78EB5689A

P577

Q37672483-3C59AD21-3470-4D34-8075-5F4E60570AE0

P698

Q37672483-0A6CC757-8635-4B3B-A749-5999BE0DF2F2

P921

Q37672483-0FD34F69-19ED-49C4-B3BD-0E3CE3AA9085

Q37672483-5A792A4C-283E-41D4-A392-B5A5A5DD363F

Q37672483-5B90237F-D71A-40FC-9865-855AB103793E

Q37672483-BFDB865A-ED79-42D3-A73B-15160136A4C5

P932

Q37672483-FE0CC430-2A2C-4D1F-8D00-C0EAB7FDBB29

P356

S11912-017-0566-9

P1433

Current Oncology Reports

P1476

Cabozantinib: an Active Novel Multikinase Inhibitor in Renal Cell Carcinoma.

@en

P2093

Gisela Schwab

http://www.w3.org/2001/XMLSchema#string

Nizar M Tannir

http://www.w3.org/2001/XMLSchema#string

Viktor Grünwald

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 4.0 International

P2860

Sequential pathogenesis of metastatic VHL mutant clear cell renal cell carcinoma: putting it together with a translational perspective

MET: a critical player in tumorigenesis and therapeutic target

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene

Phase 1 dose escalation trial of the safety and pharmacokinetics of cabozantinib concurrent with temozolomide and radiotherapy or temozolomide after radiotherapy in newly diagnosed patients with high-grade gliomas.

The von Hippel-Lindau tumor suppressor gene inhibits hepatocyte growth factor/scatter factor-induced invasion and branching morphogenesis in renal carcinoma cells

Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy

Prognostic significance of bone metastases and bisphosphonate therapy in patients with renal cell carcinoma.

Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas.

Cabozantinib in progressive medullary thyroid cancer.

P2888

s11912-017-0566-9

P304

14

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11912-017-0566-9

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

19

http://www.w3.org/2001/XMLSchema#string

P5008

P577

2017-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28247252

http://www.w3.org/2001/XMLSchema#string

P921

renal cell carcinoma

mechanism of action

P932

5331092

http://www.w3.org/2001/XMLSchema#string